Engineered T cells for cancer treatment

Usanarat Anurathapan; Ann M. Leen; Malcolm K. Brenner; Juan F. Vera

doi:10.1016/j.jcyt.2013.10.002

Engineered T cells for cancer treatment

Usanarat Anurathapan
, Ann M. Leen
, Malcolm K. Brenner
, Juan F. Vera

Texas Children's Hospital

Research output: Contribution to journal › Article › peer-review

23 Citations (Scopus)

Abstract

Adoptively transferred T cells have the capacity to traffic to distant tumor sites, infiltrate fibrotic tissue and kill antigen-expressing tumor cells. Various groups have investigated different genetic engineering strategies designed to enhance tumor specificity, increase T cell potency, improve proliferation, persistence or migratory capacity and increase safety. This review focuses on recent developments in T cell engineering, discusses the clinical application of these engineered cell products and outlines future prospects for this therapeutic modality.

Original language	English
Pages (from-to)	713-733
Number of pages	21
Journal	Cytotherapy
Volume	16
Issue number	6
DOIs	https://doi.org/10.1016/j.jcyt.2013.10.002
Publication status	Published - Jun 2014
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

CAR T cells
Cancer treatment
Genetic modification of T cells
Immunotherapy

Access to Document

10.1016/j.jcyt.2013.10.002

Cite this

@article{d4ab67f682504ae283e5ac47ce8f7844,

title = "Engineered T cells for cancer treatment",

abstract = "Adoptively transferred T cells have the capacity to traffic to distant tumor sites, infiltrate fibrotic tissue and kill antigen-expressing tumor cells. Various groups have investigated different genetic engineering strategies designed to enhance tumor specificity, increase T cell potency, improve proliferation, persistence or migratory capacity and increase safety. This review focuses on recent developments in T cell engineering, discusses the clinical application of these engineered cell products and outlines future prospects for this therapeutic modality.",

keywords = "CAR T cells, Cancer treatment, Genetic modification of T cells, Immunotherapy",

author = "Usanarat Anurathapan and Leen, \{Ann M.\} and Brenner, \{Malcolm K.\} and Vera, \{Juan F.\}",

year = "2014",

month = jun,

doi = "10.1016/j.jcyt.2013.10.002",

language = "English",

volume = "16",

pages = "713--733",

journal = "Cytotherapy",

issn = "1465-3249",

publisher = "Elsevier B.V.",

number = "6",

}

TY - JOUR

T1 - Engineered T cells for cancer treatment

AU - Anurathapan, Usanarat

AU - Leen, Ann M.

AU - Brenner, Malcolm K.

AU - Vera, Juan F.

PY - 2014/6

Y1 - 2014/6

N2 - Adoptively transferred T cells have the capacity to traffic to distant tumor sites, infiltrate fibrotic tissue and kill antigen-expressing tumor cells. Various groups have investigated different genetic engineering strategies designed to enhance tumor specificity, increase T cell potency, improve proliferation, persistence or migratory capacity and increase safety. This review focuses on recent developments in T cell engineering, discusses the clinical application of these engineered cell products and outlines future prospects for this therapeutic modality.

AB - Adoptively transferred T cells have the capacity to traffic to distant tumor sites, infiltrate fibrotic tissue and kill antigen-expressing tumor cells. Various groups have investigated different genetic engineering strategies designed to enhance tumor specificity, increase T cell potency, improve proliferation, persistence or migratory capacity and increase safety. This review focuses on recent developments in T cell engineering, discusses the clinical application of these engineered cell products and outlines future prospects for this therapeutic modality.

KW - CAR T cells

KW - Cancer treatment

KW - Genetic modification of T cells

KW - Immunotherapy

UR - https://www.scopus.com/pages/publications/84899932784

U2 - 10.1016/j.jcyt.2013.10.002

DO - 10.1016/j.jcyt.2013.10.002

M3 - Article

C2 - 24239105

AN - SCOPUS:84899932784

SN - 1465-3249

VL - 16

SP - 713

EP - 733

JO - Cytotherapy

JF - Cytotherapy

IS - 6

ER -

Engineered T cells for cancer treatment

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this